Real-world experience with 11C-methionine positron emission tomography in the management of acromegaly.

IF 5.3 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Linus Haberbosch, James MacFarlane, Olympia Koulouri, Daniel Gillett, Andrew S Powlson, Sue Oddy, David J Halsall, Kevin A Huynh, Jonathan Jones, Heok K Cheow, Joachim Spranger, Knut Mai, Christian J Strasburger, Richard J Mannion, Mark Gurnell
{"title":"Real-world experience with 11C-methionine positron emission tomography in the management of acromegaly.","authors":"Linus Haberbosch, James MacFarlane, Olympia Koulouri, Daniel Gillett, Andrew S Powlson, Sue Oddy, David J Halsall, Kevin A Huynh, Jonathan Jones, Heok K Cheow, Joachim Spranger, Knut Mai, Christian J Strasburger, Richard J Mannion, Mark Gurnell","doi":"10.1093/ejendo/lvae028","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>L-[methyl-11C]-methionine-positron emission tomography (Met-PET) is a potentially important imaging adjunct in the diagnostic workup of pituitary adenomas, including somatotroph tumors. Met-PET can identify residual or occult disease and make definitive therapies accessible to a subgroup of patients who would otherwise require lifelong medical therapy. However, existing data on its use are still limited to small case series. Here, we report the largest single-center experience (n = 61) in acromegaly.</p><p><strong>Methods: </strong>A total of 189 cases of acromegaly were referred to our national Met-PET service in the last 12 years. For this analysis, we have reviewed outcomes in those 61 patients managed exclusively by our multidisciplinary team (single center, single surgeon). Referral indications were as follows: indeterminate magnetic resonance imaging (MRI; n = 38, 62.3%), occult residual (n = 14, 23.0%), (radio-)surgical planning (n = 6, 9.8%), and occult de novo tumor (n = 3, 4.9%).</p><p><strong>Results: </strong>A total of 33/61 patients (54.1%) underwent PET-guided surgery. Twenty-four of 33 patients (72.7%) achieved complete biochemical remission following (re-)surgery. Insulin-like growth factor 1 levels were reduced to <2 × upper limit of normal (ULN) in 6 of the remaining 9 cases, 3 of whom achieved levels of <1.1 × ULN compared with mean preoperative levels of 2.4 × ULN (SD 0.8) for n = 9. Only 3 patients developed single new hormonal deficits (gonadotropic/thyrotropic insufficiency). There were no neurovascular complications after surgery.</p><p><strong>Conclusion: </strong>In patients with persistent/recurrent acromegaly or occult tumors, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. L-[methyl-11C]-methionine-positron emission tomography should therefore be considered in all patients who are potential candidates for further surgical intervention but present no clear target on MRI.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejendo/lvae028","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: L-[methyl-11C]-methionine-positron emission tomography (Met-PET) is a potentially important imaging adjunct in the diagnostic workup of pituitary adenomas, including somatotroph tumors. Met-PET can identify residual or occult disease and make definitive therapies accessible to a subgroup of patients who would otherwise require lifelong medical therapy. However, existing data on its use are still limited to small case series. Here, we report the largest single-center experience (n = 61) in acromegaly.

Methods: A total of 189 cases of acromegaly were referred to our national Met-PET service in the last 12 years. For this analysis, we have reviewed outcomes in those 61 patients managed exclusively by our multidisciplinary team (single center, single surgeon). Referral indications were as follows: indeterminate magnetic resonance imaging (MRI; n = 38, 62.3%), occult residual (n = 14, 23.0%), (radio-)surgical planning (n = 6, 9.8%), and occult de novo tumor (n = 3, 4.9%).

Results: A total of 33/61 patients (54.1%) underwent PET-guided surgery. Twenty-four of 33 patients (72.7%) achieved complete biochemical remission following (re-)surgery. Insulin-like growth factor 1 levels were reduced to <2 × upper limit of normal (ULN) in 6 of the remaining 9 cases, 3 of whom achieved levels of <1.1 × ULN compared with mean preoperative levels of 2.4 × ULN (SD 0.8) for n = 9. Only 3 patients developed single new hormonal deficits (gonadotropic/thyrotropic insufficiency). There were no neurovascular complications after surgery.

Conclusion: In patients with persistent/recurrent acromegaly or occult tumors, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. L-[methyl-11C]-methionine-positron emission tomography should therefore be considered in all patients who are potential candidates for further surgical intervention but present no clear target on MRI.

11C-蛋氨酸 PET 治疗肢端肥大症的实际经验。
背景:L-[甲基-11C]-蛋氨酸正电子发射断层扫描(Met-PET)是垂体腺瘤(包括嗜体细胞瘤)诊断工作中一种潜在的重要辅助成像手段。Met-PET可以识别残留或隐匿性疾病,并使原本需要终生接受药物治疗的一部分患者能够接受明确的治疗。然而,有关其应用的现有数据仍局限于小型病例系列。在此,我们报告了单个中心在肢端肥大症方面最大规模的经验(N=61)。方法:在过去 12 年中,189 例肢端肥大症患者被转诊到我们的国家 Met-PET 服务机构。在本次分析中,我们回顾了完全由我们的多学科团队(单中心、单外科医生)管理的 61 例患者的治疗结果。转诊指征包括:磁共振成像不确定(38 例,62.3%)、隐匿性残留(14 例,23.0%)、(放射)手术计划(6 例,9.8%)、隐匿性新发肿瘤(3 例,4.9%):33/61 例患者(54.1%)接受了 PET 指导下的手术。结果:33/61 例患者(54.1%)在 PET 指导下接受了手术,24/33 例患者(72.7%)在(再次)手术后获得了完全生化缓解。IGF-1水平降至结论水平:对于持续/复发性肢端肥大症或隐匿性肿瘤患者,Met-PET可促进进一步的靶向干预(手术/放射外科)。在大多数病例(24/33)中,Met-PET 可使病情完全缓解或明显好转,并发症风险相对较低。因此,所有可能接受进一步手术治疗,但核磁共振成像没有明确靶点的患者都应考虑进行 Met-PET 检查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Journal of Endocrinology
European Journal of Endocrinology 医学-内分泌学与代谢
CiteScore
9.80
自引率
3.40%
发文量
354
审稿时长
1 months
期刊介绍: European Journal of Endocrinology is the official journal of the European Society of Endocrinology. Its predecessor journal is Acta Endocrinologica. The journal publishes high-quality original clinical and translational research papers and reviews in paediatric and adult endocrinology, as well as clinical practice guidelines, position statements and debates. Case reports will only be considered if they represent exceptional insights or advances in clinical endocrinology. Topics covered include, but are not limited to, Adrenal and Steroid, Bone and Mineral Metabolism, Hormones and Cancer, Pituitary and Hypothalamus, Thyroid and Reproduction. In the field of Diabetes, Obesity and Metabolism we welcome manuscripts addressing endocrine mechanisms of disease and its complications, management of obesity/diabetes in the context of other endocrine conditions, or aspects of complex disease management. Reports may encompass natural history studies, mechanistic studies, or clinical trials. Equal consideration is given to all manuscripts in English from any country.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信